Articles tagged with Positron Emission Tomography
The first total-body PET/CT scanner has shown promising results in enhancing image quality, reducing scan time, and lowering dose. Clinical trials have demonstrated improved diagnostic capabilities with minimal impact on patient exposure.
Researchers at Washington University have developed a new method for precise drug delivery using cavitation dose painting, which combines focused ultrasound with ultrasound therapy to target specific locations in the body. This technique uses passive cavitation imaging to predict where a drug goes and how much is delivered.
Researchers have developed a novel PET/CT tracer that detects and characterizes blood clots in the legs, where conventional imaging has limitations. The new imaging agent may provide more accurate diagnoses and information on clot growth or embolization, leading to changes in clinical intervention.
Researchers use new PET scan technique to show that people with PTLDS have elevated levels of a chemical marker of brain inflammation, compared to healthy controls. The study suggests new avenues for treating the long-term fatigue and cognitive symptoms associated with PTLDS.
A 58-year-old female patient with advanced Alzheimer's disease showed significant improvement in brain metabolism and symptoms after undergoing hyperbaric oxygen therapy. The patient reported increased energy, mood, and cognitive function, and experienced reduced anxiety and disorientation.
A study using PET technology found that dopamine release in the brain happens twice during a meal: first when eating and second when food reaches the stomach. This release is linked to brain regions involved in reward, sensory perception, and higher cognitive functions.
Recent advancements in prostate imaging modalities have significantly enhanced the diagnosis of prostate cancer. Androgen receptor-based imaging is emerging as a promising approach for non-invasive detection using non-steroidal antiandrogen agents.
A study using a PET scan tracer has identified epigenetic differences between the brains of individuals with schizophrenia and those of unaffected participants. Reduced histone deacetylase (HDAC) levels were observed in the dorsolateral prefrontal cortex, which is important for executive functions affected by schizophrenia.
Researchers used PET scans to track TB drug levels in a rabbit model and human patients, revealing that current treatments may not be effective due to poor penetration of the drug into infected brain lesions. The study aims to optimize treatment by tailoring doses for individual patients based on imaging results.
A new second-generation positron emission tomography (PET) tracer has been identified for imaging tau pathology in Alzheimer's disease patients. The tracer, 18F-RO-948, showed promising results in a human evaluation study, outperforming other novel tau-specific radiopharmaceuticals.
A new study found that repetitive subconcussive head impacts in youth football can alter the corpus callosum, a critical band of nerve fibers connecting the two halves of the brain. This change may lead to greater risk of cognitive and motor problems in these young athletes.
The EXPLORER scanner captures a 3-D picture of the whole human body at once, producing images in as little as one second. It can track specially tagged drugs and has countless applications in diagnostics, disease progression, and new drug therapies.
Researchers developed a precision-medicine platform that uses genomic data, biospecimen measurements, and other inputs to create personalized treatment plans for mild Alzheimer's disease and at-risk individuals. The study showed significant improvements in memory function scores for 80% of participants.
Researchers used PSMA PET/CT to detect prostate cancer outside the prostate gland with higher sensitivity and specificity than standard imaging techniques. This improved accuracy enables more precisely targeted treatment, potentially increasing the chances of successful outcomes.
A new method for treating and preventing acute kidney injury (AKI) has been developed using tiny, self-assembling forms of DNA origami nanostructures. These nanostructures were shown to protect the kidneys from harm as effectively as the leading drug therapy and alleviate symptoms of AKI.
A new study published in Radiology uses deep learning to predict Alzheimer's disease from brain imaging, achieving 100% sensitivity in detecting the disease an average of more than six years prior to final diagnosis. The algorithm has the potential to complement existing tests and provide opportunities for early intervention.
A new preclinical study shows that PET imaging with the 18F-FAC radiotracer can image T cells in the liver, potentially reducing biopsies and improving treatment. The approach could lead to personalized treatment of patients with immune-related liver disease.
A new PET imaging radiotracer, <sup> 18 </sup> F-XTRA, was tested on adults to study the distribution of the α4β2 nicotinic acetylcholine receptor in the brain. The research found that the radiotracer rapidly entered the brain and distributed quickly, with lower binding in the hippocampus with healthy aging.
The study evaluated [18F]SRF101, a PET radiotracer for astrocytosis detection. The results showed no systemic signs of toxicity in mice and estimated the human radiation dosimetry to be comparable to other 18F radiopharmaceuticals.
A new Ontario clinical study shows adding PET imaging to CT scans can change treatment plans for women with locally advanced cervix cancer. The study found that patients who received PET scans were twice as likely to have a change in their treatment, leading to more extensive radiation therapy.
A recent study highlights the potential for misinterpretation of Prostate-Specific Membrane Antigen (PSMA) PET results, which can affect diagnostic accuracy and guide therapy. Researchers urge nuclear medicine physicians to analyze PSMA-ligand uptake in conjunction with lesion localization to avoid misdiagnosis.
Researchers have developed a novel PET imaging method that can measure beta-cell mass, enhancing the ability to monitor and guide diabetes therapies. The new imaging method uses a radioligand to identify beta cells and has shown promising results in differentiating between healthy individuals and those with type 1 diabetes.
Researchers have developed a new method to directly measure synaptic loss in individuals with Alzheimer's disease, using PET imaging technology. The study found that participants with Alzheimer's disease had a 41% reduction in synaptic density compared to those with normal cognition.
A new PET imaging method evaluates the extent of rheumatoid arthritis inflammation by targeting translocator protein (TSPO) expression in joint lining tissue. The study demonstrates that TSPO PET can image not only synovial macrophages but also activated synovial fibroblasts, a critical process in RA pathogenesis.
Researchers at McGill University used sMRI and PET scans to track brain degeneration in early-stage Alzheimer's disease, revealing a link between cholinergic neurons and cortical regions. The study suggests that combining PET with sMRI may be a powerful tool for diagnosing Alzheimer's before cognitive symptoms appear.
The Society of Nuclear Medicine and Molecular Imaging's 65th Annual Meeting showcased advancements in theranostics, quantitative nuclear imaging, and multimodality molecular imaging. Key findings include improved diagnostic accuracy and treatment options for various diseases, highlighting the potential for precision health.
A novel intelligent theranostic agent was designed to target tumors, with the ability to self-assemble in the tumor microenvironment and activate for therapy guided by photoacoustic imaging. The clusters showed high selectivity to the tumor microenvironment and eliminated tumor growth without subsequent recurrence.
A new molecular imaging method allows early assessment of gene therapy success, potentially improving treatment for Parkinson's and Alzheimer's diseases. The PET reporter gene/probe system enables noninvasive monitoring of gene expression in all brain areas.
Researchers have developed a novel nuclear medicine probe that can detect synaptic density loss in the brain, a key biomarker for neurodegenerative diseases like Alzheimer's. The probe, using positron emission tomography (PET) imaging, has high imaging characteristics and is suitable for clinical trials and commercialization.
Simon Cherry has made significant contributions to biomedical imaging instrumentation and technology development, including microPET and hybrid PET/MRI systems. He is widely recognized for his work on molecular imaging and has received numerous awards for his achievements.
Researchers developed a novel PSMA-targeting agent by conjugating MCG with an albumin-binding Evans blue derivative, improving tumor delivery and increasing the therapeutic effect. The agent showed significant tumor growth inhibition and complete eradication of tumors in mice, suggesting a promising strategy for cancer management.
A novel PET tracer has been developed to accurately image cardiovascular infections, which are extremely dangerous and have a high fatality rate. The tracer, called 6'-[18F]Fluoromaltotriose, is transported into bacterial cells by a membrane transport system exclusive to bacteria, allowing for specific imaging of bacterial infections.
Two Phase I/II clinical studies, PROter and PROfind, evaluate the safety and efficacy of radiolabeled PSMA-R2 for prostate cancer treatment. The trials assess tumor activity and patient response to treatment.
A new study reveals that having a meal increases oxygen consumption in human brown adipose tissue (BAT) as much as cold exposure does. This finding suggests that eating may be an effective way to activate BAT and support metabolic health.
A novel PET imaging method uses antibody fragment probes to target immune cells, detecting inflammation in the bowel and potentially guiding biopsies. The technique has wide applications in various diseases and could unlock assessment of inflammation.
A new trial presented at ASCO18 shows that PET scans can improve treatment outcomes for esophageal cancer patients. Patients who responded to induction chemotherapy had a median overall survival of 46 months, while those who did not respond had a 27-month median survival, significantly better than previous studies.
Scientists have developed a new approach to cancer therapy by combining two synergistic drug components into a dimer, which can be loaded into polymeric nanotransporters at exceptionally high concentration. This method reduces side effects and improves transport and accumulation of drugs in tumors.
The University of Alberta has successfully produced enough medical isotopes for 1,000 diagnostic procedures a day using a particle accelerator called a cyclotron. This innovation addresses the shortage of technetium-99m, a crucial isotope used in cancer diagnosis and treatment.
Researchers at ETH Zurich have developed a marker substance to visualize NMDA receptors on nerve cells using positron emission tomography (PET). This will aid in researching various brain diseases like Alzheimer's, Parkinson's, and depression. The PET tracer may also help determine the correct dosage of drugs influencing NMDA receptor ...
A new PET tracer has shown potential in predicting treatment effectiveness for depression by measuring the level of serotonin transporter protein in the brain. The study found that patients who responded to treatment had lower levels of this protein before treatment began, suggesting a biomarker for remission.
Researchers have developed a new PET imaging agent that targets NMDA receptors in nerve cells to assess treatments for various neurological diseases. The agent, C-Me-NB1, provides valuable insights into the role of NMDA receptors in brain disorders.
Researchers at Massachusetts General Hospital developed an artificial intelligence technique, AUTOMAP, that enables the production of high-quality images in less time and with lower doses. This approach uses deep learning to automatically determine the correct image reconstruction algorithm, allowing for instant feedback during scanning.
A study by Intermountain Medical Center found that PET scans detected severe obstructive coronary artery disease at a rate of 79% compared to 70% for SPECT scans. Additionally, PET scans identified patients who did not need an invasive procedure more accurately than SPECT scans.
A new PET scan-compatible imaging agent can detect specific mutations in lung cancer tumors, predicting treatment success. Over 80% of patients with detected mutations showed positive response to targeted drug, while those without signals saw limited benefits.
Researchers developed a novel small molecule PET tracer to noninvasively detect EGFR mutation status in NSCLC patients. The approach showed high accuracy and potential for predicting treatment response and monitoring dynamic changes during therapy.
Researchers developed a new approach that uses a single PET scan to assess PD-L1 positive tumors, enabling personalized cancer treatment. The study demonstrates the feasibility of this non-invasive method, which may help guide treatment decisions and assess treatment response.
A new imaging test can detect bone marrow engraftment as early as days after a transplant, giving patients and doctors a more accurate assessment of the treatment's success. This breakthrough could help patients avoid painful biopsies and rapidly respond to potential complications, potentially saving lives.
A new study by CAMH reveals that long-term depression causes significant brain inflammation, which may require different treatment strategies. The research suggests that the condition is not a static disease but rather progressive and requires unique therapeutics.
Researchers have developed a novel PET tracer that can measure damage from multiple sclerosis by targeting potassium channels, providing quantitative information about underlying biochemical processes. This breakthrough has the potential to improve diagnosis and monitoring for MS patients.
A study published in the journal Brain uses a combination of imaging techniques to examine tau build-up in patients with Alzheimer's disease and progressive supranuclear palsy. The findings support the transneuronal spread hypothesis, suggesting that tau starts in one place and spreads throughout the brain.
The Society of Nuclear Medicine and Molecular Imaging has published appropriate use criteria (AUC) for somatostatin receptor PET imaging in neuroendocrine tumors. This AUC addresses several clinical scenarios for diagnosing neuroendocrine tumors (NETs).
The new total-body PET/CT scanner will advance clinical research and patient care by providing better imaging data from the whole body, reducing radiation exposure and increasing sensitivity. This technology has the potential to change cancer detection and staging methods, as well as improve diagnosis for other systemic conditions.
A new nuclear medicine test can identify kidney transplant infection in non-invasive procedures, using positron emission tomography/magnetic resonance imaging (PET/MRI). The test has the potential to refine characterization of infectious and inflammatory kidney diseases.
The study reveals that β-amyloid accumulation occurs in the inner parts of the brain within the default mode network. This finding holds significant implications for future research studies and clinical diagnosis of Alzheimer's disease.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/CT imaging in cancer patients. The AUC aims to improve the utilization of this technology and provide guidance for providers across specialties.
Researchers at Penn are building a positron emission tomography (PET) scanner that can image a patient's entire body at once, allowing them to see both glucose and glutamine on the same scan. This will enable better understanding of how these two compounds interact with cancer cells.
Androgen receptor targeted imaging is emerging as a potential modality for early, rapid, and efficient diagnosis of prostate cancer. Current medical imaging reviews discuss traditional diagnostic approaches and summarize current imaging approaches using PSMA, BN, and AR targeted imaging.
A novel PET tracer, 6"-18F-fluoromaltotriose, has been developed to identify most bacterial infections. The agent is a derivative of maltose and targets the maltodextrin transporter in bacteria, allowing for non-invasive detection and monitoring of antibiotic therapy.
Researchers used PET imaging to study brain inflammation following Zika virus infection in mice, finding a 2- to 6-fold increase in global brain neuroinflammation over time. The technology allows for longitudinal studies of the same animal during the course of the infection, providing enhanced information about disease progression.
Researchers at Lund University have developed an imaging method that shows changes in the brain associated with Alzheimer's disease at different stages of life. The method uses a PET camera and a trace substance to detect tau protein and can facilitate diagnosis and treatment for younger patients.